Black men less willing to be investigated for prostate cancer

March 01, 2015

The incidence of prostate cancer among men of Afro-Caribbean origin is higher than in white men, they are more likely to be diagnosed as emergencies and their mortality rates are higher. Until now it has been unclear why these disappointing outcomes exist.

To investigate the possible effects of patients' preferences and choices, a team led by the University of Exeter Medical School carried out a study in more than 500 men attending general practices in Bristol. The research was supported by the NIHR Collaboration for Leadership in Applied Health Research and Care South West Peninsula (PenCLAHRC).

The men were presented with realistic hypothetical scenarios - each included a description of a prostate cancer symptom and the estimated risk of prostate cancer. Working with colleagues at the Universities of Bristol and UCL, the researchers found that preference for investigation was lower in black men irrespective of the risk presented in the scenario. This difference was strongest in relation to the scenarios associated with the lowest risk level, with just 44 per cent of black males opting for investigation compared with 91 per cent of white males. In both groups, the most common reason for declining investigation was low risk, but significantly more black men stated that they simply did not want to know if they had cancer.

The study, published on March 2 in the British Journal of General Practice (BJGP), was led by Tanimola Martins, at the University of Exeter Medical School. He said: "We know that black men are significantly more likely to develop prostate cancer, and are more likely to die from it. For the first time, this study has found evidence that black men are less willing than white men to be tested for the disease. GPs should be aware of the reduced appetite for testing in black males, which may be linked to fear and a perception that treatment may lead to severe complications. Doctors could consider proactively discussing the subject. Education targeted at the black community and the health professionals who treat them may also help to address this."

Professor Willie Hamilton, of the University of Exeter Medical School, outlined the next steps. He said: "We know that black people have worse outcomes with other cancers, particularly breast cancer. To address this, we need to understand the reasons behind that, and this could be a significant step on that journey."

Dr Jonathan Banks, one of the study's co-authors from the University of Bristol's Centre for Academic Primary Care, said: "The findings help us understand some of the reasons why black males have a lower preference for investigation in prostate cancer. We hope these findings may lead to new ways to help educate the black community and the health professionals who treat them about symptoms and the importance of early investigation."
-end-


University of Exeter

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.